Carmustine

Generic Name
Carmustine
Brand Names
Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
Drug Type
Small Molecule
Chemical Formula
C5H9Cl2N3O2
CAS Number
154-93-8
Unique Ingredient Identifier
U68WG3173Y
Background

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions
Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

First Posted Date
2008-07-29
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT00723658
Locations
🇺🇸

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States

🇺🇸

St. Joseph Mercy Oakland, Pontiac, Michigan, United States

🇺🇸

Sparrow Regional Cancer Center, Lansing, Michigan, United States

and more 26 locations

Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Phase 2
Conditions
Lymphoma
First Posted Date
2008-07-22
Last Posted Date
2013-08-02
Lead Sponsor
Cancer Research UK
Target Recruit Count
25
Registration Number
NCT00720447

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

First Posted Date
2008-07-16
Last Posted Date
2024-07-18
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
53
Registration Number
NCT00716066
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

🇺🇸

Swedish Medical Center-First Hill, Seattle, Washington, United States

🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

First Posted Date
2008-06-11
Last Posted Date
2018-07-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
122
Registration Number
NCT00695409
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

First Posted Date
2008-06-05
Last Posted Date
2017-06-28
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
48
Registration Number
NCT00691015
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

First Posted Date
2008-05-01
Last Posted Date
2013-08-26
Lead Sponsor
Cancer Research UK
Target Recruit Count
60
Registration Number
NCT00669812
Locations
🇬🇧

Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

First Posted Date
2008-04-30
Last Posted Date
2022-05-18
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
12
Registration Number
NCT00669669
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

First Posted Date
2008-03-24
Last Posted Date
2024-02-22
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
25
Registration Number
NCT00641381
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

First Posted Date
2008-03-11
Last Posted Date
2020-04-27
Lead Sponsor
University of California, San Francisco
Target Recruit Count
21
Registration Number
NCT00632827
Locations
🇺🇸

Washington University, Saint Louis, Missouri, United States

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

First Posted Date
2008-01-11
Last Posted Date
2021-02-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT00591630
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy